Table 4. Various research findings of SLN formulations with their lipid, method of preparation, route of administration .
| Drug | Route of administration | Lipid | Size | %Entrapment Efficiency | Reference |
| Curcumin | I.V | Compritol 888 ATO | 9.51nm | - | 124 |
| CdSEe/ZnS | I.V | - | - | - | 125 |
| - | I.V | Stearic acid | 159-239 nm | 126 | |
| Doxorubicin | I.V | Stearic acid | 80-90 ± 5 nm | 101 | |
| Paclitaxel (PTX) and TOs-Cisplatin | I.V | Glyceride monostearate | 108.6 ± 3.1 nm | 90.3 ± 3.2% | 127 |
| Methotrexate (MTX) | I.V | Stearyl amine | 174.51± 5.1 nm | 84.3 ± 1.24 % | 128 |
| Nitrendipine (NDP) | I.V and Intraduodenal | Trimyristin, tripalmitin, tristearin, soy phosphatidylcholine 95% | 101.9 ± 3 nm | 99.8 ± 0.23 % | 129 |
| Idebenone | I.V. route | Cetyl palmitate | 30 -95 nm | 66 | |
| Repaglinide (RG) | Oral | Stearic acid |
360± 2.5 nm (Solvent injection) 281±5.3 nm (Ultrasonication) |
62.14 ± 1.29% | 121 |
| Carbamazepine | Oral |
Tristearin, Phospholipon 80 H |
168±1.8 nm | 62.14 % | 130 |
| Elvitegravir | Oral | Gelucire 44/14 | 151.0±2.4- 199.1±2.7 nm | 89.7±0.27% | 131 |
| Insulin | Oral | Cetyl palmitate | 361±30 nm | 46±6 % | 105 |
| Ramipril | Oral | Glyceryl monostearate, glyceryl monooleate | 104-334 nm | 72.5 ± 86.40% | 132 |
| Glibenclamide (GLI) | Oral | Precirol and compritol | 105.1±2.9-183.1±3.2 nm | 80±5% | 133 |
| Carvedilol (CVD) | Oral | Precirol ATO5 |
20±0.009 – 58±2.09 nm |
78±5.17-94±3.71% | 134 |
| Buspirone HCl | Oral | Cetyl Alcohol | 345.7 nm | ---- | 135 |
| Donepezil (DPL) | Intranasal | Glyceryl monostearate | 121.0 nm | 67.95% | 136 |
| Agomelatine | Intranasal | Glyceryl tripalmitate, Gelucire 43/01, Glyceryl tristeratae, Stearic acid, Precirol, and Galeol | 220.90 ± 1.55-515.30±2.40 nm | 58.19± 8.10-93.68 ±3.4% | 117 |
| Rifabutin (RFB) | P.A | Glyceryl dibehenate, glyceryl tristearate | 92 ± 1 nm | 91.2±3.6% | 137 |
| Ethambutol (EMB) | P.A | Compritol | 56.25±2.05- 81.86±3.20 nm | 98.16±0.66-99.04±0.4% | 138 |
| Triamcinolone acetonide | P.A | Soya lecithin | 339.2 ± 1.85 nm | 58.23±1.8% | 119 |
| Naringenin (NRG) | P.A | Glyceryl monostearate | 98 nm | 79.11% | 139 |
| Paclitaxel (PTX) | P.A | 140 | |||
| Avanafil (AVA) | T.D | Compritol 888, Cholesterol, Castor oil | 86 nm | 85.01% | 108 |
| Diclofenac Sodium (DS) | T.D | 89% | 141 | ||
| Triptolide(TPL) | T.D | Compritol 888 ATO | 104 ± 1.82 nm | 92.8± 8.52% | 142 |
| Ivermectin (IVM) | T.D | Palmitic acid | 312.8 ±2.4 nm | 98.48± 0.052% | 143 |
| Isoniazid(INH) | O.D |
Compritol 888: Stearic acid(4:1) |
316.5± 8.7 nm | 65.2± 2.2% | 144 |
| Natamycin (NAT) | O.D | Precirol ATO5 | 21.8- 47.48 nm | 41.06-83.2% | 145 |
| Cyclosporine | O.D | 355±11- 487±32 nm | 71±1-100±1% | 146 | |
| Alendronate | P.A | Compritol 888: | <100 nm | - | 147 |
| Triamcinolone Acetonide-(TA) | O.D | Stearic acid | 80±11.1 nm | 100% | 122 |
T.D=Transdermal Delivery, O.D= Ocular Delivery, P.A = Pulmonary administration